{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:15:49Z","timestamp":1783984549052,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2020019"],"award-info":[{"award-number":["2020019"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["964874"],"award-info":[{"award-number":["964874"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40263-024-01079-y","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T14:01:48Z","timestamp":1713448908000},"page":"473-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-7396","authenticated-orcid":false,"given":"Hasan \u00c7a\u011f\u0131n","family":"Lenk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-7076","authenticated-orcid":false,"given":"Robert L\u00f8vsletten","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-8795","authenticated-orcid":false,"given":"Kevin S.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-3568","authenticated-orcid":false,"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-2751","authenticated-orcid":false,"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"1079_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216\u201329. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050503.","journal-title":"Am J Psychiatry"},{"key":"1079_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","volume":"220","author":"D Siskind","year":"2022","unstructured":"Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220:115\u201320. https:\/\/doi.org\/10.1192\/bjp.2021.61.","journal-title":"Br J Psychiatry"},{"key":"1079_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3.","journal-title":"Lancet"},{"issue":"Suppl 8","key":"1079_CR4","first-page":"14","volume":"61","author":"DD Miller","year":"2000","unstructured":"Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000;61(Suppl 8):14\u20137.","journal-title":"J Clin Psychiatry"},{"key":"1079_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","volume":"27","author":"OD Howes","year":"2022","unstructured":"Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry. 2022;27:58\u201372. https:\/\/doi.org\/10.1038\/s41380-021-01200-3.","journal-title":"Mol Psychiatry"},{"key":"1079_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007.","journal-title":"Pharmacol Ther"},{"key":"1079_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1515\/dmdi.2006.21.3-4.187","volume":"21","author":"J Hasselstr\u00f8m","year":"2006","unstructured":"Hasselstr\u00f8m J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact. 2006;21:187\u2013211. https:\/\/doi.org\/10.1515\/dmdi.2006.21.3-4.187.","journal-title":"Drug Metabol Drug Interact"},{"key":"1079_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177\u201393. https:\/\/doi.org\/10.2165\/00003088-199937030-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1079_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/acps.12794","volume":"136","author":"I Castberg","year":"2017","unstructured":"Castberg I, Westin AA, Skogvoll E, Spigset O. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 2017;136:455\u201364. https:\/\/doi.org\/10.1111\/acps.12794.","journal-title":"Acta Psychiatr Scand"},{"key":"1079_CR10","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1111\/bcp.15849","volume":"89","author":"V Solhaug","year":"2023","unstructured":"Solhaug V, Tveito M, Waade RB, H\u00f8iseth G, Molden E, Smith RL. Impact of age, sex and cytochrome P450 genotype on quetiapine and N-desalkylquetiapine serum concentrations: a study based on real-world data from 8118 patients. Br J Clin Pharmacol. 2023;89:3503\u201311. https:\/\/doi.org\/10.1111\/bcp.15849.","journal-title":"Br J Clin Pharmacol"},{"key":"1079_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/acps.13228","volume":"142","author":"E Wagner","year":"2020","unstructured":"Wagner E, McMahon L, Falkai P, Hasan A, Siskind D. Impact of smoking behavior on clozapine blood levels\u2014a systematic review and meta-analysis. Acta Psychiatr Scand. 2020;142:456\u201366. https:\/\/doi.org\/10.1111\/acps.13228.","journal-title":"Acta Psychiatr Scand"},{"key":"1079_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","volume":"24","author":"E Skogh","year":"2002","unstructured":"Skogh E, Reis M, Dahl M-L, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518.","journal-title":"Ther Drug Monit"},{"key":"1079_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/JCP.0000000000001126","volume":"39","author":"M Tveito","year":"2019","unstructured":"Tveito M, Smith RL, H\u00f8iseth G, Molden E. The effect of valproic acid on olanzapine serum concentration: a study including 2791 patients treated with olanzapine tablets or long-acting injections. J Clin Psychopharmacol. 2019;39:561\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000001126.","journal-title":"J Clin Psychopharmacol"},{"key":"1079_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.tips.2022.09.011","volume":"43","author":"M Jukic","year":"2022","unstructured":"Jukic M, Milosavljevi\u0107 F, Molden E, Ingelman-Sundberg M. Pharmacogenomics in treatment of depression and psychosis: an update. Trends Pharmacol Sci. 2022;43:1055\u201369. https:\/\/doi.org\/10.1016\/j.tips.2022.09.011.","journal-title":"Trends Pharmacol Sci"},{"key":"1079_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41537-020-0107-7","volume":"6","author":"L Kylles\u00f8","year":"2020","unstructured":"Kylles\u00f8 L, Smith RL, Karlstad \u00d8, Andreassen OA, Molden E. Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. npj Schizophr. 2020;6:1\u20136. https:\/\/doi.org\/10.1038\/s41537-020-0107-7.","journal-title":"npj Schizophr"},{"key":"1079_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/acps.12825","volume":"137","author":"R McCutcheon","year":"2018","unstructured":"McCutcheon R, Beck K, D\u2019Ambrosio E, Donocik J, Gobjila C, Jauhar S, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018;137:39\u201346. https:\/\/doi.org\/10.1111\/acps.12825.","journal-title":"Acta Psychiatr Scand"},{"key":"1079_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.05.033","volume":"168","author":"J de Leon","year":"2020","unstructured":"de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology. 2020;168: 107656. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.033.","journal-title":"Neuropharmacology"},{"key":"1079_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","volume":"27","author":"WK Kennedy","year":"2013","unstructured":"Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27:1021\u201348. https:\/\/doi.org\/10.1007\/s40263-013-0114-6.","journal-title":"CNS Drugs"},{"key":"1079_CR19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1600991","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51: e1. https:\/\/doi.org\/10.1055\/s-0037-1600991.","journal-title":"Pharmacopsychiatry"},{"key":"1079_CR20","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.4088\/JCP.19cs13169","volume":"81","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020;81:3649. https:\/\/doi.org\/10.4088\/JCP.19cs13169.","journal-title":"J Clin Psychiatry"},{"key":"1079_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2246","author":"MM Juki\u0107","year":"2021","unstructured":"Juki\u0107 MM, Smith RL, Molden E, Ingelman-Sundberg M. Evaluation of the CYP2D6 haplotype activity scores based on metabolic ratios of 4,700 patients treated with three different CYP2D6 substrates. Clin Pharmacol Ther. 2021. https:\/\/doi.org\/10.1002\/cpt.2246.","journal-title":"Clin Pharmacol Ther"},{"key":"1079_CR22","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2021. https:\/\/www.R-project.org\/. Accessed 2024 Feb 12."},{"key":"1079_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cpt.2571","volume":"111","author":"H\u00c7 Lenk","year":"2022","unstructured":"Lenk H\u00c7, Kl\u00f6ditz K, Johansson I, Smith RL, Juki\u0107 MM, Molden E, et al. The polymorphic nuclear factor NFIB regulates hepatic CYP2D6 expression and influences risperidone metabolism in psychiatric patients. Clin Pharmacol Ther. 2022;111:1165\u201374. https:\/\/doi.org\/10.1002\/cpt.2571.","journal-title":"Clin Pharmacol Ther"},{"key":"1079_CR24","doi-asserted-by":"publisher","unstructured":"Murray AJ, Rogers JC, Katshu MZUH, Liddle PF, Upthegrove R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front Psychiatry [Internet]. 2021 [cited 2024 Feb 12];12. https:\/\/doi.org\/10.3389\/fpsyt.2021.703452.","DOI":"10.3389\/fpsyt.2021.703452"},{"key":"1079_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.737716","volume":"16","author":"M Konstandi","year":"2022","unstructured":"Konstandi M, Johnson EO, Lang MA. Stress as a potential regulatory factor in the outcome of pharmacotherapy. Front Neurosci. 2022;16: 737716. https:\/\/doi.org\/10.3389\/fnins.2022.737716.","journal-title":"Front Neurosci"},{"key":"1079_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","volume":"6","author":"MM Juki\u0107","year":"2019","unstructured":"Juki\u0107 MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019;6:418\u201326. https:\/\/doi.org\/10.1016\/S2215-0366(19)30088-4.","journal-title":"Lancet Psychiatry"},{"key":"1079_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","volume":"175","author":"MM Juki\u0107","year":"2018","unstructured":"Juki\u0107 MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry. 2018;175:463\u201370. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17050550.","journal-title":"Am J Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01079-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01079-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:37:35Z","timestamp":1715877455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01079-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01079-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"29 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by the University of Oslo (incl Oslo University Hospital). This work was supported by South-Eastern Norway Regional Health Authority (Grant No. 2020019) and the European Union's Horizon 2020 research and innovation program (REALMENT; Grant No. 964874).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"OAA is consultant to Cortechs.ai and received speaker\u2019s honoraria from Lundbeck, Sunovion, Janssen. The other authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Regional Committee for Medical and Health Research Ethics and the Hospital Investigational Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Since only historical data from already performed routine analyses was included in the study without posing any risk or burden to the patients, patient consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that supports the findings of this study are available from the corresponding author upon reasonable request. The data is not publicly available due to privacy and ethical restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"H\u00c7L and RLS extracted and prepared the data material. H\u00c7L, RLS, and EM analysed and interpreted the data. EM designed the study. H\u00c7L drafted the initial manuscript. All authors critically reviewed, wrote, edited, and significantly contributed to the final manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}